# Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months

> **NCT00200512** · PHASE2,PHASE3 · COMPLETED · sponsor: **Mylan Bertek Pharmaceuticals** · enrollment: 16 (—)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** apomorphine HCl injection

## Key facts

- **NCT ID:** NCT00200512
- **Lead sponsor:** Mylan Bertek Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-09
- **Primary completion:** —
- **Final completion:** 1999-11
- **Target enrollment:** 16 (—)
- **Last updated:** 2005-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00200512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00200512, "Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00200512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*